Auckland, 12 September 2008 – A2 Corporation (NZAX: ATM) (A2C) has sent to shareholders today a Notice of Special Meeting relating to a meeting to be held at 3pm on 26th September, immediately following the Company’s Annual Meeting on the same day.
The Special Meeting has been called to consider and if appropriate ratify the recent placements of new shares to Child Health Research Foundation (CHRF) and AMP Capital Investors. Shareholders have also been asked to approve a placement of 50,000,000 new shares in the Company at an issue price of 10 cents per share to an investment fund associated with the Chicago-based Equity Group Investments, LLC. The placement to EGI-Fund (08-10) Investors, LLC (EGI) will raise gross proceeds of $5.0 million.
Cliff Cook, Chairman of A2C said “We are delighted to be in a position to put to shareholders these resolutions relating to the commitments being made by various leading organisations. As a result of the recently completed rights issue, the placement to AMP Capital Investors and other NZ based institutional investors, and the proposed placement to EGI, A2C will be in a very strong financial position to take the business forward. The funds raised will ensure the Company can take advantage of the opportunities in front of it without a requirement to return to minority shareholders for further capital.”
Mountain Road Investments Limited (MRI) (48.08% shareholder in the Company) is entitled to vote and has indicated it will vote in favour of the resolutions. None of AMP Capital Investors, CHRF or EGI is associated with MRI.
For more information please contact:
Cliff Cook, Chairman, A2 Corporation, Ph +64 9 309 1700
Anthony Lawler, CEO A2 Corporation, Ph +64 9 523 4795
Julien Leys, JML Communications, Mobile +64 21 655 598
About A2 Corporation
A2 Corporation Ltd owns and licenses intellectual property that enables the identification of cattle for the production and subsequent marketing of a2 Milk™. a2 Milk™ is naturally produced to contain maximum amounts of a milk protein variant that is associated by a number of studies with potential benefits in some individuals. A2 Corporation Ltd receives royalty income from sales of a2 Milk™ products and testing for A2 cattle, and shares in the profits or losses of associates and subsidiaries formed for those purposes.